Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118727 · ClinicalTrials.gov registry record · Phase 2
Therapy in Amyotrophic Lateral Sclerosis (TAME)
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02118727 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 89 participants.
The verdict
NCT02118727, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD)
Interventions
- DRUG Memantine
- DRUG Placebo (for Memantine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2021-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02118727
The ClinicalTrials.gov registry entry for NCT02118727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Memantine is the first listed.
NCT02118727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02118727 about?
NCT02118727 is a clinical study titled "Therapy in Amyotrophic Lateral Sclerosis (TAME)". The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used bo...
What is the current status of trial NCT02118727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2018-11-07. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT02118727?
The interventions under investigation include: Memantine (DRUG), Placebo (for Memantine) (DRUG).
Who is sponsoring clinical trial NCT02118727?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.